Introduction: Current therapeutics for osteogenesis imperfecta (OI), a heritable connective tissue disorder characterized by skeletal fragility and impaired bone cell function, are limited to bisphosphonates. Soluble activin receptor type IIB (sActRIIB) decoy molecules, which bind transforming growth factor-β (TGF-β) ligands, including myostatin and activin A, have increased skeletal bone properties in murine models of OI, […]
9. Combined Inhibition of Myostatin and Activin A Enhances Femoral Microarchitecture and Strength in a Type I/IV Osteogenesis Imperfecta Mouse Model
